New Mutation in ParE in a Pneumococcal In Vitro Mutant Resistant to Fluoroquinolones

AUTOR(ES)

Janoir, Claire

FONTE

American Society for Microbiology

RESUMO

For an in vitro mutant of Streptococcus pneumoniae selected on moxifloxacin four- to eightfold-increased MICs of new fluoroquinolones, only a twofold-increased MIC of ciprofloxacin, and a twofold-decreased MIC of novobiocin were observed. This phenotype was conferred by two mutations: Ser81Phe in GyrA and a novel undescribed His103Tyr mutation in ParE, outside the quinolone resistance-determining region, in the putative ATP-binding site of topoisomerase IV.

Documentos Relacionados

• High-Level Resistance to Fluoroquinolones Linked to Mutations in gyrA, parC, and parE in Salmonella enterica Serovar Schwarzengrund Isolates from Humans in Taiwan
• Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parE Loci
• Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.
• Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates of Streptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season
• Prevalence of Mutations within the Quinolone Resistance-Determining Region of gyrA, gyrB, parC, and parE and Association with Antibiotic Resistance in Quinolone-Resistant Salmonella enterica